Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 8.15 SEK 2% Market Closed
Market Cap: 1.9B SEK

Wall Street
Price Targets

VICO Price Targets Summary
Vicore Pharma Holding AB

Wall Street analysts forecast VICO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VICO is 29.49 SEK with a low forecast of 15.15 SEK and a high forecast of 40.86 SEK.

Lowest
Price Target
15.15 SEK
86% Upside
Average
Price Target
29.49 SEK
262% Upside
Highest
Price Target
40.86 SEK
401% Upside
Vicore Pharma Holding AB Competitors:
Price Targets
CRNX
Crinetics Pharmaceuticals Inc
160% Upside
CSL
CSL Ltd
31% Upside
145020
Hugel Inc
17% Upside
EDIT
Editas Medicine Inc
141% Upside
2256
Abbisko Cayman Ltd
37% Upside
NVAX
Novavax Inc
134% Upside
NTRA
Natera Inc
30% Upside
ORKA
Oruka Therapeutics Inc
271% Upside

Revenue
Forecast

Revenue Estimate
Vicore Pharma Holding AB

For the last 8 years the compound annual growth rate for Vicore Pharma Holding AB's revenue is 83%. The projected CAGR for the next 3 years is -21%.

83%
Past Growth
-21%
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Vicore Pharma Holding AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Vicore Pharma Holding AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VICO's stock price target?
Price Target
29.49 SEK

According to Wall Street analysts, the average 1-year price target for VICO is 29.49 SEK with a low forecast of 15.15 SEK and a high forecast of 40.86 SEK.

What is Vicore Pharma Holding AB's Revenue forecast?
Projected CAGR
-21%

For the last 8 years the compound annual growth rate for Vicore Pharma Holding AB's revenue is 83%. The projected CAGR for the next 3 years is -21%.

Back to Top